Immediate Impact
19 standout
Citing Papers
Unveiling the potential of CLL-1: a promising target for AML therapy
2025 Standout
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
2023 Standout
Works of Françoise Boyer being referenced
Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc
2013
Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis
2010
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Françoise Boyer | 135 | 105 | 76 | 14 | 158 | |
| Zoë C. Wong | 64 | 74 | 45 | 13 | 190 | |
| Katharina Goetze | 63 | 69 | 92 | 19 | 200 | |
| Agostino Antolino | 111 | 107 | 21 | 14 | 164 | |
| Blanca Navarro | 128 | 98 | 105 | 15 | 173 | |
| Anna Kioumi | 133 | 126 | 34 | 19 | 199 | |
| Tomáš Jurček | 71 | 116 | 35 | 16 | 145 | |
| James R Bailey | 71 | 33 | 76 | 10 | 190 | |
| Juliana Teo | 32 | 41 | 102 | 11 | 192 | |
| Benoît De Renzis | 87 | 114 | 66 | 15 | 135 | |
| Nadja Jäkel | 104 | 122 | 81 | 12 | 177 |
All Works
Loading papers...